Thymidylate synthase gene copy number as a predictive marker for response to pemetrexed treatment of lung adenocarcinoma

Anticancer Research

Volumn 33, Issue 5, 2013, Pages 1935-1940

  Kasai, Daishi ^a   Ozasa, Hiroaki ^a   Oguri, Tetsuya ^a   Miyazaki, Mikinori ^a   Uemura, Takehiro ^a   Takakuwa, Osamu ^a   Kunii, Eiji ^a   Ohkubo, Hirotsugu ^a   Maeno, Ken ^a   Niimi, Akio ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Gene amplification; Non small cell lung cancer; Pemeterexed; Thymidylate synthase

Indexed keywords

CARBOPLATIN; CISPLATIN; GENOMIC DNA; PEMETREXED; THYMIDYLATE SYNTHASE;

ARTICLE; BONE METASTASIS; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CELL ASSAY; CELL VIABILITY; DRUG EFFICACY; GENE DOSAGE; HUMAN; HUMAN TISSUE; IC 50; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; TUMOR BIOPSY;

GENE AMPLIFICATION; NON-SMALL CELL LUNG CANCER; PEMETEREXED; THYMIDYLATE SYNTHASE;

ADENOCARCINOMA; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; GENE DOSAGE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; THYMIDYLATE SYNTHASE; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84878212799     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP and Gandara D: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small cell lung cancer. J Clin Oncol 26(21): 3543-3551, 2008.
2. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L and Bunn PA Jr.: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 22: 1589-1597, 2004. (Pubitemid 41079796)
3. Grønberg BH, Bremnes RM, Fløtten O, Amundsen T, Brunsvig PF, Hjelde HH, Kaasa S, von Plessen C, Stornes F, Tollåli T, Wammer F, Aasebø U and Sundstrøm S: Phase III study by the Norwegian Lung Cancer Study Group: Pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 27 (19): 3217-3224, 2009.
4. Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C and Gridelli C: Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small cell lung cancer (PARAMOUNT): A double-blind, phase 3, randomised controlled trial. Lancet Oncol 13(3): 247-255, 2012.
5. Adjei AA: Pemetrexed: A multitargeted antifolate agent with promising activity in solid tumors. Ann Oncol 11: 1335-1341, 2000.
6. Shih C, Habeck LL, Mendelsohn LG, Chen VJ and Schultz RM: Multiple folate enzyme inhibition: Mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA). Adv Enzyme Regul 38: 135-152, 1998. (Pubitemid 28381388)
7. Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, Shackelford KA, Mendelsohn LG, Soose DJ, Patel VF, Andis SL, Bewley JR, Rayl EA, Moroson BA, Beardsley GP, Kohler W, Ratnam M and Schultz RM: LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 57: 1116-1123, 1997. (Pubitemid 27138611)
8. Chattopadhyay S, Moran RG and Goldman ID: Pemetrexed: Biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther 6: 404-417, 2007. (Pubitemid 46332443)
9. Sigmond J, Backus HH, Wouters D, Temmink OH, Jansen G and Peters GJ: Induction of resistance to the multitargeted antifolate pemetrexed (Alimta) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Biochem Pharmacol 66: 431-438, 2003. (Pubitemid 36937028)
10. Longley DB, Ferguson PR, Boyer J, Latif T, Lynch M, Maxwell P, Harkin DP and Johnston PG: Characterization of a thymidylate synthase (TS)-inducible cell line: A model system for studying sensitivity to TS- and non-TS-targeted chemotherapies. Clin Cancer Res 11: 3533-3539, 2001. (Pubitemid 33069991)
11. Ozasa H, Oguri T, Uemura T, Miyazaki M, Maeno K, Sato S and Ueda R: Significance of thymidylate synthase for resistance to pemetrexed in lung cancer. Cancer Sci 101(1): 161-166, 2010.
12. Takezawa K, Okamoto I, Okamoto W, Takeda M, Sakai K, Tsukioka S, Kuwata K, Yamaguchi H, Nishio K and Nakagawa K: Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer. Br J Cancer 104(10): 1594-1601, 2011.
13. Sun JM, Han J, Ahn JS, Park K and Ahn MJ: Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy. J Thorac Oncol 6(8): 1392-1399, 2011.
14. Gomez HL, Santillana SL, Vallejos CS, Velarde R, Sanchez J, Wang X, Bauer NL, Hockett RD, Chen VJ, Niyikiza C and Hanauske AR: A phase II trial of pemetrexed in advanced breast cancer: Clinical response and association with molecular target expression. Clin Cancer Res 12(3 Pt 1): 832-838, 2006. (Pubitemid 43259865)
15. Righi L, Papotti MG, Ceppi P, Billè A, Bacillo E, Molinaro L, Ruffini E, Scagliotti GV and Selvaggi G: Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. J Clin Oncol 28(9): 1534-1539, 2010.
16. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D and Verweij J: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2): 228-247, 2009.
17. Oguri T, Achiwa H, Bessho Y, Muramatsu H, Maeda H, Niimi T, Sato S and Ueda R: The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells. Lung Cancer 49: 345-351, 2005. (Pubitemid 41139147)
18. Ceppi P, Volante M, Saviozzi S, Rapa I, Novello S, Cambieri A, Lo Iacono M, Cappia S, Papotti M and Scagliotti GV: Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 107: 1589-1596, 2006. (Pubitemid 44546920)
19. Tanaka F, Wada H, Fukui Y and Fukushima M: Thymidylate synthase (TS) gene expression in primary lung cancer patients: A large-scale study in Japanese population. Ann Oncol 22(8): 1791-1797, 2011.
20. Chu E, Callender MA, Farrell MP and Schmitz JC: Thymidylate synthase inhibitors as anticancer agents: From bench to bedside. Cancer Chemother Pharmacol 52: S80-89, 2003. (Pubitemid 37047028)
21. Ooyama A, Okayama Y, Takechi T, Sugimoto Y, Oka T and Fukushima M: Genome-wide screening of loci associated with drug resistance to 5-fluorouracil-based drugs. Cancer Sci 98(4): 577-583, 2007. (Pubitemid 46562750)
22. Gosens MJ, Moerland E, Lemmens VP, Rutten HT, Tan-Go I and Van den Brule AJ: Thymidylate synthase genotyping is more predictive for therapy response than immunohistochemistry in patients with colon cancer. Int J Cancer 123(8): 1941-1949, 2008.
23. Wynes MW, Konopa K, Singh S, Reyna-Asuncion B, Ranger-Moore J, Sternau A, Christoph DC, Dziadziuszko R, Jassem J and Hirsch FR: Thymidylate synthase protein expression by IHC and gene copy number by SISH correlate and show great variability in non-small cell lung cancer. J Thorac Oncol 7 (6): 982-992, 2012.